PDCD1 and cutaneous melanoma: Recently, BioNTech announced a strategic collaboration with Regeneron to initiate the phase II clinical trial combining BNT111 with Regeneron Libtayo (cemiplimab), a fully humanized anti-PD-1 therapy in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma [351].